Shares of NeoGenomics (NASDAQ:NEO) rose 1% after the company reported Q2 results.
Earnings per share fell 157.14% over the past year to ($0.04), which beat the estimate of ($0.10).
Revenue of $86,977,000 decreased by 14.49% from the same period last year, which beat the estimate of $86,120,000.
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: Jul 28, 2020
Time: 08:30 AM
ET Webcast URL: https://www.webcaster4.com/Webcast/Page/1219/35578
52-week high: $37.70
52-week low: $18.52
Price action over last quarter: Up 18.70%
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services.
See more from Benzinga
- Earnings Scheduled For July 28, 2020
- Stocks That Hit 52-Week Highs On Friday
- Stocks That Hit 52-Week Highs On Thursday
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.